4:07 PM ET
10-Q
Financial Results
Fennec Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $4.64M
Fennec Pharmaceuticals reported a significant increase in total revenue to $19.6 million for Q3 2026, driven by PEDMARK product sales. The company achieved net income of $4.6 million compared to a net loss in the prior year, supported by a decrease in G&A expenses and improved operating margins. Cash reserves stood at $48.7 million, which management expects will be sufficient to fund operations based on the current plan.
- Key figure
- Net income $4.64M